Zelgen(SH:688266) Xin Lang Zheng Quan·2025-09-15 01:52Group 1 - The core viewpoint of the news is that Zai Lab has shown significant stock performance with an 84.38% increase year-to-date, despite a recent decline in the last five trading days [1] - As of September 15, Zai Lab's stock price reached 114.89 CNY per share, with a market capitalization of 30.412 billion CNY [1] - The company has a primary business focus on the research, production, and sales of chemical and biological new drugs, with 99.97% of its revenue coming from pharmaceuticals [1] Group 2 - As of June 30, 2025, Zai Lab reported a revenue of 376 million CNY, reflecting a year-on-year growth of 56.07%, while the net profit attributable to shareholders was -72.8035 million CNY, a decrease of 9.42% [2] - The number of shareholders increased to 8,795, marking a 16.75% rise, while the average circulating shares per person decreased by 14.35% to 30,097 shares [2] - Notable institutional shareholders include China Europe Medical Health Mixed A and GF Healthcare Stock A, with changes in their holdings compared to the previous period [2]